3-benzyloxy-5-ethoxybenzoic acid | 1452587-49-3

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: 3-benzyloxy-5-ethoxybenzoic acid
• 英文别名: 3-Ethoxy-5-phenylmethoxybenzoic acid
• CAS: 1452587-49-3
• 化学式: C₁₆H₁₆O₄
• 分子量: 272.301
• InChiKey: SEUGDFXVLMYBKZ-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.3
• 重原子数：
  20
• 可旋转键数：
  6
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.19
• 拓扑面积：
  55.8
• 氢给体数：
  1
• 氢受体数：
  4

反应信息

• 作为反应物：
  描述：

  3-benzyloxy-5-ethoxybenzoic acid 在 氯化亚砜 、 三乙胺 、 N,N-二甲基甲酰胺 作用下， 以 四氢呋喃 为溶剂， 反应 24.0h， 生成 N-(2-acetyl-4-(pyrrolidin-1-yl)phenyl)-3-(benzyloxy)-5-ethoxybenzamide
  参考文献：
  名称：

  Design, synthesis, and mechanism of action of 2-(3-hydroxy-5-methoxyphenyl)-6-pyrrolidinylquinolin-4-one as a potent anticancer lead

  摘要：

  New 6- (or 6,7-) substituted 2-(hydroxyl substituted phenyl)quinolin-4-one derivatives were synthesized and screened for antiproliferative effects against cancer cell lines. Structure-activity relationship correlations were established and the most promising compound 2-(3-hydroxy-5-methoxyphenyl)-6-pyrrolidin-1-ylquinolin-4-one (6h) exhibited strong inhibitory activity against various human cancer cell lines, particularly non-small cell lung cancer NCI-H522. Additional studies suggested a mechanism of action resembling that of the antimitotic drug vincristine. The presence of a C-ring OH group in 6h will allow this compound to be converted readily to a water soluble and physicochemically stable hydrophilic prodrug. Compound 6h is proposed as a new anticancer lead compound. (C) 2013 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2013.06.083

文献信息

• N-terminal modified cyclopeptidic mimetics of ApolloTBM as inhibitors of TRF2
  作者：Xia Chen、Yao Dong、Tianyue Guo、Chao-Yie Yang、Yong Chen、Haiying Sun

  DOI：10.1016/j.bmcl.2020.127401

  日期：2020.11

  compounds which can bind to the TRFH domain of TRF2 and block the interactions between TRF2 and its associated proteins is crucial for elucidating the molecular mechanisms of these protein–protein interactions. Using a previously identified peptidic mimetic of ApolloTBM as a lead compound, we designed and synthesized a series of novel TRF2 inhibitors by non-peptidic modifications of the N-terminal residues

  端粒重复序列结合因子2（TRF2）在保护端粒免于被DNA断裂识别中起重要作用。TRF2通过其TRF同源性（TFRH）域将大量辅助蛋白募集到端粒中，从而部分地发挥其端粒保护功能。鉴定可与TRF2的TRFH结构域结合并阻断TRF2及其相关蛋白之间相互作用的小分子化合物，对于阐明这些蛋白与蛋白相互作用的分子机制至关重要。使用先前鉴定的Apollo TBM肽模拟物作为先导化合物，我们通过N的非肽修饰设计并合成了一系列新型TRF2抑制剂-末端残基。这些化合物可以保持与TRF2的结合亲和力，但与前导化合物相比，其肽段特性大大降低。
• Protease inhibitors
  申请人：SmithKline Beecham Corporation

  公开号：US20020173469A1

  公开（公告）日：2002-11-21

  The present invention provides compounds which inhibit proteases, including cathepsin K, pharmaceutical compositions of such compounds, and methods for treating diseases of excessive bone loss or cartilage or matrix degradation, including osteoporosis; gingival disease including gingivitis and periodontitis; arthritis, more specifically, osteoarthritis and rheumatoid arthritis; Paget's disease; hypercalcemia of malignancy; and metabolic bone disease, comprising inhibiting said bone loss or excessive cartilage or matrix degradation by administering to a patient in need thereof a compound of the present invention.

  本发明提供了一种抑制蛋白酶的化合物，包括卡他普星K，以及这些化合物的药物组合物和治疗骨量过度流失或软骨或基质降解疾病的方法，包括骨质疏松症；牙龈疾病，包括牙龈炎和牙周炎；关节炎，更具体地说是骨关节炎和类风湿性关节炎；帕吉特病；恶性高钙血症；以及代谢性骨病，通过向需要治疗的患者投与本发明的化合物来抑制骨量过度流失或过度软骨或基质降解。
• PROTEASE INHIBITORS
  申请人：SMITHKLINE BEECHAM CORPORATION

  公开号：EP0934291A1

  公开（公告）日：1999-08-11
• EP0934291A4
  申请人：——

  公开号：EP0934291A4

  公开（公告）日：1999-08-11
• US5998470A
  申请人：——

  公开号：US5998470A

  公开（公告）日：1999-12-07